An analysis of data from the REDUCE-IT trial of icosapent ethyl (IPE) in patients with hypertriglyceridaemia and at high cardiovascular risk has shown considerable variability in Lp(a) levels, especially in those with relatively high baseline levels or certain demographic and clinical characteristics.1
